Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab, Carboplatin, and Paclitaxel in Neoadjuvant Triple-Negative Inflammatory Breast Cancer
NCT02876107Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2016
- Primary completion
- Oct 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of panitumumab in breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2016; status: active, not recruiting.
02
Drugs
panitumumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02876107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02876107.